- Khiron is the first company to receive authorization to
commercialize high-THC medical cannabis magistral preparations from
Colombia's National Narcotics
Fund
- Authorization is supplementary to the previously announced
high-THC extraction and cultivation quotas from the Colombian
Technical Quotas Group
- Effective immediately, prescriptions will be filled through
Company's ILANS clinics, with expanded distribution in Colombia as partner pharmacies receive
dispensary permits
- Company's ILANS clinics are fully authorized to dispense
Khiron's high-THC products for various indications including
chronic pain, nausea and vomiting associated with chemotherapy
TORONTO, May 20, 2020 /CNW/ - Khiron Life Sciences Corp.
("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF),
(Frankfurt: A2JMZC), a vertically
integrated cannabis leader with core operations in Latin America and Europe, announced today that it has received
authorization from Colombia's
National Narcotics Fund for the sale of magistral preparation of
high-THC medical cannabis. With this authorization Khiron becomes
the first and, to date, only company fully authorized to
manufacture and sell high-THC medical cannabis for patient
prescriptions in Colombia.
"The authorization from Colombia's National Narcotics Fund
demonstrates our continued ability to meet regulatory requirements,
and as a result we today begin to sell high-THC medical cannabis
product in Colombia. With our
clinics, training and infrastructure in place our high-THC product
offers an important alternative for patients living with chronic
pain, nausea and vomiting associated with chemotherapy, and
continues Khiron's mission to improve the quality of life for
patients in Colombia and across
Latin America," comments
Juan Diego Alvarez, Khiron
Vice-President of Regulatory Affairs.
Initial high-THC product prescriptions under the National
Narcotics Fund authorization will be filled through the
Company's fully owned ILANS clinics which are in receipt of
high-THC dispensary authorization. Distribution will expand as
Khiron's Colombian pharmacy partners receive dispensing
authorization, which is anticipated in Q3 2020.
About Khiron Life Sciences Corp.
Khiron Life Sciences
Corp. is the dominant integrated medical cannabis company in
Latin America. Khiron has core
operations in Latin America, along
with activity in North America and
Europe, and is licensed in
Colombia for the cultivation,
production, domestic distribution, and international export of both
tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis.
The Company delivers best in class regulatory compliance, is fully
authorized to manufacture and fill prescriptions for high- and
low-THC medical cannabis in Colombia, and has the first approved line of
CBD cosmetic products on shelf in Colombia, and available in
the United States and the
United Kingdom.
With a focused regional strategy and patient oriented
approach, the Company combines global scientific expertise,
agricultural advantages, branded product market entrance
experience and education to drive prescription and brand
loyalty to address priority medical conditions such as chronic
pain, epilepsy, depression and anxiety in the Latin American
market of over 620 million people. The Company is led by Co-founder
and Chief Executive Officer, Alvaro
Torres, together with an experienced executive team,
and a knowledgeable Board of Directors that includes former
President of Mexico, Vicente Fox.
Visit Khiron online at www.khiron.ca and on Instagram
@khironlife
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment analyses,
expectations or statements made by third-parties in respect of
Khiron, its securities, or financial or operating results (as
applicable). Although Khiron believes that the expectations
reflected in forward-looking statements in this press release are
reasonable, such forward-looking statement has been based on
expectations, factors and assumptions concerning future events
which may prove to be inaccurate and are subject to numerous risks
and uncertainties, certain of which are beyond Khiron's control,
including the risk factors discussed in Khiron's Annual Information
Form which is available on Khiron's SEDAR profile
at www.sedar.com. The forward-looking information contained in
this press release is expressly qualified by this cautionary
statement and are made as of the date hereof. Khiron disclaims any
intention and has no obligation or responsibility, except as
required by law, to update or revise any forward-looking
information, whether as a result of new information, future events
or otherwise.
Neither the TSXV nor its Regulation Services Provider (as
that term is defined in the policies of the TSXV) accepts
responsibility for the adequacy or accuracy of this press
release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/khiron-begins-sales-of-first-high-thc-medical-cannabis-in-colombia-301062298.html
SOURCE Khiron Life Sciences Corp.